The complex relationship between cardiologists and lipid-lowering dietary supplements: Hate or love?
Nutrition, Metabolism and Cardiovascular Diseases · 2025
DOI: 10.1016/j.numecd.2025.104533 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2025. Verfasst von Arrigo F G Cicero und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Italy; Cardiovascular Medicine Unit, Heart, Chest and Vascular …. Hauptthemen laut MEDLINE: Dietary Supplements, Dyslipidemias, Hypolipidemic Agents, Lipids. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
In August 2025, the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) released an update of the dyslipidaemia management guidelines, including a brief statement on lipid-lowering dietary supplements. The document states that dietary supplements or vitamins lacking documented safety and significant LDL-cholesterol-lowering efficacy are not recommended to reduce ASCVD risk. This sentence has been interpreted by some as a broad discouragement against the use of nutraceuticals; however, the corresponding class of recommendation is "C", indicating reliance on expert opinion and routine practice rather than robust randomized evidence. The negative interpretation is further influenced by the recent EFSA opinion on red yeast rice, which raised safety concerns but does not extend to other nutraceuticals. Concerns regarding efficacy have also been shaped disproportionately by the SPORT trial, a short, single-blinded, underpowered study that compared a low-dose statin with a heterogeneous group of supplements, including some with no proven lipid-lowering effects. Notably, the guideline update does not address several nutraceuticals supported by meta-analyses-such as plant sterols, soluble fibers, berberine, artichoke extract, and bergamot-whose efficacy and safety are well documented. A more constructive reading of the update suggests encouraging clinicians to recommend only evidence-based nutraceuticals and motivating further research. These agents should be considered as adjuncts to lifestyle interventions in low-risk individuals, not as substitutes for pharmacologic therapy when indicated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Italy; Cardiovascular Medicine Unit, Heart, Chest and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologn…
- Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, Milan, Italy.
Zitieren
APA
Cicero, A. F. G., & Corsini, A. (2025). The complex relationship between cardiologists and lipid-lowering dietary supplements: Hate or love?. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2025.104533
Vancouver
Cicero AFG, Corsini A. The complex relationship between cardiologists and lipid-lowering dietary supplements: Hate or love?. Nutrition, Metabolism and Cardiovascular Diseases. 2025. doi:10.1016/j.numecd.2025.104533
BibTeX
@article{Cicero2025,
author = {Cicero, Arrigo F G and Corsini, Alberto},
title = {The complex relationship between cardiologists and lipid-lowering dietary supplements: Hate or love?},
journal = {Nutrition, Metabolism and Cardiovascular Diseases},
year = {2025},
doi = {10.1016/j.numecd.2025.104533}
}
EUVIMED